Authors
Latest:
The Synergistic OrganizationA key question for an organization post-M&A is: “What organizational capabilities support global guidance and leadership, and which of them require these at the 'local' level?” Scott Hull discusses potential solutions.
Latest:
A Blueprint for BalanceStephen Rivera, vice president, global technical accounting advisory services and policy, Johnson & Johnson, capitalizes on his lively personality—and a courageous career journey—to bring people together to shape the future of biopharma.
Latest:
Attacks on Pharmaceutical Improvement PatentsIs Congress harming pharmaceutical research by limiting enforcement of improvement patents?
Latest:
Attacks on Pharmaceutical Improvement PatentsIs Congress harming pharmaceutical research by limiting enforcement of improvement patents?
Latest:
Innovation + Human Engagement = Optimal Patient SupportPatient support program providers should incorporate new technologies for more effective processes, but this should be matched with empathy, human connectivity and personalized clinical interventions, writes Tommy Bramley.
Latest:
Creating Reliable Data Foundations for AISteve Gens and Remco Munnik offer five best-practice tips for achieving a definitive, trusted regulatory and product information asset base capable of supporting intelligent innovation.
Latest:
Managing the 3 Fronts of the Drug Pricing Conundrum: Policy, Creativity, CollaborationThe impacts of disruptive curative therapies and advances in the future of health will be profound. To be best positioned for success, healthcare systems under continuous cost pressure must address three key areas, writes Thomas Unger.
Latest:
Emerging Biopharma Tackles the Opioid CrisisDr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.
Latest:
Product Development: The Optimizer’s CurseReoccurring disappointment in development portfolios-why it happens and how to mitigate it.
Latest:
Why Pharma’s Approach to IDMP Today Will Matter to Patients & Physicians TomorrowThe Identification of Medicinal Products (IDMP) software industry has talked up the broader potential of data-driven processes. Pharma companies and their software providers have an important role to play in realizing these processes. Frits Stulp discusses the foundations that need to be laid for lasting transformation of pharma information access in the real world.
Latest:
Digital Talent & Real EstateBiopharma companies hungry for digital talent must evaluate their real estate portfolio and workplace strategies to access new talent pools, says Joanne Henderson.
Latest:
Pre-launch Prep: The Modern ProtocolTech-driven changes to training and learning systems-and how brand information is provided and shared-are overhauling approaches to sales rep preparation.
Latest:
Post-Launch Birthday: The Time to RefineFollowing a new product’s first year on the market, there are four key ways companies can refine commercial strategies to maximize product sales.
Latest:
Post-Launch Birthday: The Time to RefineFollowing a new product’s first year on the market, there are four key ways companies can refine commercial strategies to maximize product sales.
Latest:
To Reduce Commercial Risk for Orphan Drugs, Transform ForecastingTo successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Latest:
Pharmaceutical Native AdvertisingA look into how native advertising works, what cost benefits they provide, and measuring their success.
Latest:
Commercialization Imperatives for Success in Rare DiseasesTo ensure patients have timely access to expensive new therapies, biopharma companies have to address commercialization challenges with innovative measures, even after getting regulatory approval.
Latest:
Money Isn't Everything: Beating Salary InflationAlan White explores alternative ways for life sciences firms to keep hold of experienced, qualified professionals as demand for pharmacovigilance skills soars.
Latest:
Value-Based Agency Contracting Clears a Path to Better Outcomes for AllThe healthcare industry’s ongoing shift from volume- to value-based contracting has set a compelling precedent for forward-thinking healthcare marketing agencies.
Latest:
Value-Based Agency Contracting Clears a Path to Better Outcomes for AllThe healthcare industry’s ongoing shift from volume- to value-based contracting has set a compelling precedent for forward-thinking healthcare marketing agencies.
Latest:
Pharma 4.0: Redefining Product Development and Regulatory OperationsSathyanarayanan Krishnamurthy looks at the potential impact of Pharma 4.0 on product development and regulatory operations.
Latest:
Three Technologies that Can Move Your BrandThe rise of digital has enhanced our ability to personalize our marketing messages and engage our target audiences more effectively
Latest:
Launch Strategies: Trends and Challenges for Biotech CompaniesMichael Kleinrock, of The IQVIA Institute for Human Data Science, will moderate a panel of launch and market access experts, as they discuss how biotech companies have addressed some key challenges to achieve launch success. Specific points will include an assessment of the overall outlook, what makes launches excellent, how to determine your optimal strategy, and questions that need to be addressed when deciding whether to launch or to partner. Live: Wednesday, Oct. 23, 2019 at 10am EDT On demand available after airing until Oct. 23, 2020 Register free
Latest:
For Payer Research, High Stakes are the Mother of All InventionAs payers increasingly stifle new drug launches, investors in biopharmaceutical companies pursue better sources of insights.
Latest:
Technology and Patients Intersect at Digital Pharma EastA look at highlights from the Digital Pharma East conference looking at technology and marketing innovation in pharma.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
